Optimind Pharma Corp.
OMND
CNSX
| 11/30/2025 | 08/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 23.86% | -22.44% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 23.86% | -22.44% | |||
| Cost of Revenue | 55.81% | 14.67% | |||
| Gross Profit | -1.80% | -37.99% | |||
| SG&A Expenses | 57.59% | -6.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 56.97% | 0.00% | |||
| Operating Income | -195.74% | -570.00% | |||
| Income Before Tax | -159.49% | -3,850.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -159.49% | -3,850.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -159.49% | -3,850.00% | |||
| EBIT | -195.74% | -570.00% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -100.00% | -- | |||
| Normalized Basic EPS | -- | -- | |||
| EPS Diluted | -100.00% | -- | |||
| Normalized Diluted EPS | -- | -- | |||
| Average Basic Shares Outstanding | 0.00% | -1.49% | |||
| Average Diluted Shares Outstanding | 0.00% | -1.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||